SANDOZ MONTELUKAST 10 MG — DIN 02328593
MONTELUKAST (MONTELUKAST SODIUM) : 10 MG · SANDOZ CANADA INCORPORATED · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is SANDOZ MONTELUKAST?
SANDOZ MONTELUKAST 10 MG contains MONTELUKAST (MONTELUKAST SODIUM) : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02328593, held by SANDOZ CANADA INCORPORATED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 11-Oct-2011. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SANDOZ MONTELUKAST used for?
Sandoz Montelukast (montelukast sodium) is indicated in adult and pediatric patients 2 years of age and older for the prophylaxis and chronic treatment of asthma, including prevention of day- and night-time symptoms, and the treatment of acetylsalicylic acid (ASA)-sensitive asthmatic patients. Sandoz Montelukast is indicated for the treatment of exercise-induced bronchoconstriction in adult and pediatric patients 2 years of age and older with asthma. Sandoz Montelukast is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 15 years of age and older.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Montelukast cost around the world?
Montelukast is listed on 15 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| South Africa | single exit price | 53 | 64 | ZAR███.██ |
| Italy | prezzo al pubblico (classe A) | 26 | 59 | EUR███.██ |
| Czechia | max producer price (ex-factory) | 10 | 51 | CZK███.██ |
| Sweden | AIP (pharmacy purchase price) | 11 | 46 | SEK███.██ |
| Greece | producer price (ex-factory) | 34 | 34 | EUR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 25 | 26 | EUR███.██ |
| Slovakia | categorised final price | 17 | 26 | EUR███.██ |
| Australia | ex-manufacturer | 8 | 24 | AUD███.██ |
| Romania | max producer price | 11 | 15 | RON███.██ |
| Hungary | producer price (ex-factory) | 12 | 12 | HUF███.██ |
| Luxembourg | reimbursement | 8 | 8 | EUR███.██ |
| Spain | PVP con IVA (public price) | 5 | 5 | EUR███.██ |
| Morocco | PPV (public price) | 1 | 5 | MAD███.██ |
| United Kingdom | hospital | 4 | 4 | GBP███.██ |
| Bahrain | retail (max) | 1 | 1 | BHD███.██ |
380 pack listings across 226 brand entries and 14 price bases, refreshed 08 Sep 2026. Ranges span every Montelukast pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Montelukast in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
29 holders have a Canadian DIN containing Montelukast, across 97 DINs, of which 41 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| SANDOZ CANADA INCORPORATED | 4 | 4 | SANDOZ MONTELUKAST | Sourceable in Canada |
| TEVA CANADA LIMITED | 9 | 3 | NTP-MONTELUKAST, RATIO-MONTELUKAST, TEVA-MONTELUKAST | Sourceable in Canada |
| APOTEX INC | 6 | 3 | APO-MONTELUKAST, APO-MONTELUKAST SODIUM, APO-MONTELUKAST SODIUM CHEWABLE | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 5 | 3 | JAMP MONTELUKAST CHEWABLE TABLETS, JAMP-MONTELUKAST | Sourceable in Canada |
| ORGANON CANADA INC. | 4 | 3 | SINGULAIR | Sourceable in Canada |
| AURO PHARMA INC | 3 | 3 | AURO-MONTELUKAST, AURO-MONTELUKAST CHEWABLE TABLET | Sourceable in Canada |
| MINT PHARMACEUTICALS INC | 3 | 3 | MINT-MONTELUKAST | Sourceable in Canada |
| PHARMASCIENCE INC | 3 | 3 | PMS-MONTELUKAST, PMS-MONTELUKAST FC | Sourceable in Canada |
| PRO DOC LIMITEE | 3 | 3 | MONTELUKAST | Sourceable in Canada |
| SIVEM PHARMACEUTICALS ULC | 3 | 3 | MONTELUKAST | Sourceable in Canada |
| SANIS HEALTH INC | 3 | 2 | MONTELUKAST | Sourceable in Canada |
| MARCAN PHARMACEUTICALS INC | 6 | 1 | IPG-MONTELUKAST, MAR-MONTELUKAST | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 10 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | null |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Montelukast |
|---|---|
| ATC code | R03DC03 |
| AHFS class | 10:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02328593 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2328593 |
| Brand name | SANDOZ MONTELUKAST |
| Generic / active ingredient | MONTELUKAST (MONTELUKAST SODIUM) : 10 MG |
| Market authorization holder | SANDOZ CANADA INCORPORATED |
| Health Canada schedule | Prescription |
| ATC code | R03DC03 |
| ATC anatomical main group | R — Respiratory system |
| ATC therapeutic subgroup | R03DC |
| Current status | MARKETED |
| Status date | 11-Oct-2011 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
41 of 97 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-MONTELUKAST | 10 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | 02379236 |
| AG-MONTELUKAST | 10 MG | TABLET | ANGITA PHARMA INC. | MARKETED | 02482835 |
| APO-MONTELUKAST | 5 MG | TABLET (CHEWABLE) | APOTEX INC | MARKETED | 02377616 |
| APO-MONTELUKAST | 4 MG | TABLET (CHEWABLE) | APOTEX INC | MARKETED | 02377608 |
| APO-MONTELUKAST | 10 MG | TABLET | APOTEX INC | MARKETED | 02374609 |
| AURO-MONTELUKAST | 10 MG | TABLET | AURO PHARMA INC | MARKETED | 02401274 |
| AURO-MONTELUKAST CHEWABLE TABLET | 4 MG | TABLET (CHEWABLE) | AURO PHARMA INC | MARKETED | 02422867 |
| AURO-MONTELUKAST CHEWABLE TABLET | 5 MG | TABLET (CHEWABLE) | AURO PHARMA INC | MARKETED | 02422875 |
| BIO-MONTELUKAST | 10 MG | TABLET | BIOMED PHARMA | MARKETED | 02445735 |
| JAMP MONTELUKAST CHEWABLE TABLETS | 4 MG | TABLET (CHEWABLE) | JAMP PHARMA CORPORATION | MARKETED | 02514877 |
2 · Same class — other molecules in ATC R03DC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Montelukast | ACCEL-MONTELUKAST SODIUM TABLETS · ACH-MONTELUKAST · AG-MONTELUKAST · APO-MONTELUKAST · APO-MONTELUKAST SODIUM · APO-MONTELUKAST SODIUM CHEWABLE · AURO-MONTELUKAST · AURO-MONTELUKAST CHEWABLE TABLET · BIO-MONTELUKAST · DOM-MONTELUKAST · DOM-MONTELUKAST FC · IPG-MONTELUKAST · JAMP MONTELUKAST CHEWABLE TABLETS · JAMP-MONTELUKAST · M-MONTELUKAST · MAR-MONTELUKAST · MINT-MONTELUKAST · MONTELUKAST · MYLAN-MONTELUKAST · NAT-MONTELUKAST · NRA-MONTELUKAST · NTP-MONTELUKAST · PENDO-MONTELUKAST · PENDO-MONTELUKAST FC · PMS-MONTELUKAST · PMS-MONTELUKAST FC · PRIVA-MONTELUKAST · Q-MONTELUKAST · RAN-MONTELUKAST · RATIO-MONTELUKAST · RIVA-MONTELUKAST · RIVA-MONTELUKAST FC · SANDOZ MONTELUKAST · SINGULAIR · SPC-MONTELUKAST · TEVA-MONTELUKAST · UNI-MONTELUKAST · VAN-MONTELUKAST | 97 | 41 | Yes |
| Zafirlukast | ACCOLATE TAB 20 MG | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC R03D
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| R03DX | Benralizumab · Mepolizumab · Omalizumab · Reslizumab · Roflumilast · Tezepelumab | 19 | 17 |
| R03DA | Aminophylline · Choline Theophyllinate · Diprophylline · Theophylline · Theophylline, Combinations Excl. Psycholeptics | 82 | 8 |
| R03DB | Theophylline And Adrenergics | 1 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is SANDOZ MONTELUKAST called?
The same molecule, Montelukast, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Montelukast Viatris | Latin | Australia, Czechia, Sweden |
| Montelukast Teva | Latin | Czechia, Sweden |
| Singulair | Latin | Czechia, Morocco, Sweden |
| MONTELAR | Latin | Czechia |
| Montelukast Krka | Latin | Sweden |
| Montelukast Sandoz | Latin | Sweden |
| Singulair® | Latin | Sweden |
| CASTISPIR | Latin | Czechia |
| MONKASTA | Latin | Czechia |
| Montelukast Accord | Latin | Sweden |
| Montelukast STADA | Latin | Sweden |
| MONTELUKAST MYLAN | Latin | Czechia |
| APX-MONTELUKAST | Latin | Australia |
| Montelukast Lupin | Latin | Australia |
| MONTELUKAST MEDREG | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.